A new Scientific Statement from the Heart Failure Society of America (HFSA) challenges longstanding ambiguity in the ...

People with mildly reduced ejection fraction, a distinct group with unique needs, account for nearly one-quarter of HF cases.

SPIRIT-HF missed its primary composite endpoint at 2 years, with higher observed event rates on spironolactone versus placebo ...

TyG-BMI enhances risk stratification in hypertensive HFmrEF by integrating insulin resistance and metabolic syndrome signals that complement established biomarkers such as NT-proBNP. Multivariable ...

CHICAGO -- The novel myeloperoxidase (MPO) inhibitor mitiperstat failed to improve quality of life or functional capacity in heart failure with mid-range to preserved ejection fraction (HFmrEF, HFpEF) ...

To date, little research has focused on patients with HFmrEF. Risk of adverse outcomes was greater for patients with HFmrEF that had deteriorated versus the outcomes of patients whose HFmrEF had ...

New heart failure guidelines released in the United States today stress a four-drug-class approach in patients with reduced ejection fraction, define a new category of “mildly reduced” heart failure, ...

Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.

A trial testing the aldosterone blocker spironolactone in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) did not ...

Please provide your email address to receive an email when new articles are posted on . Approximately 52% of patients with HF are categorized as those with a preserved ejection fraction.

Please provide your email address to receive an email when new articles are posted on . “Despite this substantial clinical overlap and the recognition of AF as a potential therapeutic target in HF ...

INTRODUCTION Acute kidney injury (AKI) during hospitalization is associated with increased mortality in patients with acute heart failure (AHF). In 2016, the European Society of Cardiology introduced ...